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Elevated levels of circulating high-sensitivity C-reactive protein (hs-CRP) have been observed in 
depression, with the body mass index (BMI) being a major mediator of this association. However, the 
sex difference in the association between hs-CRP and depression remains unclear. This study aimed 
to investigate the sex difference in the association between hs-CRP and depression. Data from the 
2016 Korea National Health and Nutritional Examination Survey were used for our study. High hs-CRP 
was defined as >3.0 mg/L, while depression was determined using a cut-off score of 10 in the Patient 
Health Questionnaire-9. The study population comprised 5,483 Korean adults. Men with high hs-CRP 
levels showed statistically higher prevalence of depression than those with low hs-CRP levels (8.90% 
vs. 3.65%, P < 0.0001). The high hs-CRP group was 1.86 times more likely to have depression after 
adjusting for BMI and other covariates in men (adjusted odds ratio: 1.86; 95% confidence interval: 1.07–
3.25; P = 0.029). Meanwhile, no statistically significant association between hs-CRP and depression was 
found among women. Depression was considerably associated with hs-CRP only in men, indicating a 
biological difference between men and women that can independently modify the relationship between 
hs-CRP and depression.
Increasing evidence supports that depression is associated with inflammatory response1,2. Systemic immune acti-
vation, i.e., increased levels of pro-inflammatory cytokines and changes in the acute-phase protein response, 
has been reported in major depression3,4. Therefore, depression may be viewed as a psychoneuroimmunological 
disorder that shows persistent inflammation3.
C-reactive protein (CRP) is a positive acute response protein that is related to systemic inflammation5. 
Elevated levels of circulating CRP have been observed in depression6–9, but the exact association between high 
CRP and depression is unclear10–12. Although CRP levels are generally only elevated in severe inflammation, the 
development of high-sensitivity assays (e.g., hs-CRP test) allowed for the quantification of low CRP levels in 
healthy individuals. Thus, studies on the clinical role of hs-CRP in the association between low-grade systemic 
inflammation and depression are expected to be undertaken.
Several studies have investigated the association between depression and CRP according to sex, but the results 
are conflicting. A 1-year observation showed that major depression was strongly associated with increased levels 
of CRP in men13. In a cohort study conducted in northern Finland, although the association of depression with 
hs-CRP was not considerable in women, elevated hs-CRP levels (≥1.0 mg/L) increased the probability for severe 
current and recurrent depressive episodes in men by 1.7-fold and 3.1-fold, respectively14. A study using 6-year 
data from the National Health and Nutrition Examination Survey (NHANES) also showed that CRP remained 
profoundly associated with depression in a dose-response fashion in men, but not in women15. By contrast, a 
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retrospective cohort study of 1,494 female patients reported that hs-CRP is an independent risk factor for de 
novo major depressive disorder in women8. In a study using combined data of two Copenhagen population-based 
studies of 73,131 samples, elevated CRP levels were associated with increased risk for depression after adjusting 
for covariates including sex9.
The body mass index (BMI, kg/m2) has been reported to be a major mediator of the inflammation-depression asso-
ciation4. In an epidemiological study, CRP was associated with depression only in obese men16. A study of 13,006 adults 
from the NHANES showed no association between CRP and depression after adjusting for BMI15. Moreover, abnormal 
body weight, both under- and overweight, has been suggested to profoundly influence the relationship between CRP 
and depression. In the US general population, higher BMI was reported to be associated with higher CRP concentra-
tions17. Given that the adipose tissue of people with obesity secretes higher amounts of inflammatory molecules includ-
ing CRP18,19, it is possible that the BMI-CRP association is at least in part related with depression.
Given these results, we aimed to investigate the probability that depression differed in men and women with 
different hs-CRP levels. In addition, we also aimed to evaluate the effect of the association between hs-CRP and 
depression after adjusting for covariates including BMI in the Korean general population, which comprise indi-
viduals with relatively lower BMI than that of the Western population.
Results
Descriptive statistics. The study comprised 5,483 participants; of these, 2,373 were men and 3,110 were 
women. The general characteristics of the study population by sex are shown in Table 1. A total of 4.17% and 
7.52% male and female participants had depression, respectively. Men with high hs-CRP levels showed a statis-
tically higher prevalence of depression compared to men with low hs-CRP levels (8.90% vs. 3.65%, P < 0.0001). 
Meanwhile, the prevalence of depression in women was not significantly different between the groups of high and 
low hs-CRP levels (9.79% vs. 7.34%, P = 0.215).
In general, men with depression tended to have low educational level, low house income, current unmarried 
status, be smoking, have more chronic medical disease, and low BMI. Meanwhile, no statistical difference for age, 
alcohol use, and residential area by prevalence of depression was noted among men. For women participants, 
all variables reached considerable difference according to prevalence of depression, except hs-CRP, alcohol use 
status, and residential area.
Sex difference of the association between hs-CRP and depression. Table 2 shows the results of multivar-
iate logistic regression analysis for the association of depression with hs-CRP. In men, the high hs-CRP group was 1.86 
times more likely to have depression after adjusting for covariates (adjusted Odds Ratio (OR): 1.86; 95% Confidence 
Interval (CI): 1.07–3.25; P = 0.029). Low house income, unmarried status, smoking, and two or more chronic medical 
diseases were found to considerably increase the probability of depression in men. Meanwhile, age, educational level, 
alcohol use, residential area, and BMI showed no substantial difference in the prevalence of depression in men.
There were no significant associations between hs-CRP levels and depression in the women participants 
(adjusted OR: 1.10; 95% CI: 0.67–1.80; P = 0.704). Age was found to have inverse correlation with the prevalence 
of depression in women. Low educational level, low house income, smoking, and chronic medical conditions 
were associated with increased probability of depression in women. Meanwhile, alcohol use, residential area, 
BMI, and menopausal status was not associated with depression in women. The detailed results of multivariate 
logistic regression are shown in Table 2.
When we performed multiple linear regression analysis using hs-CRP and PHQ-9 score for depression as 
continuous variables, the association between the two variables remained significant in men (β = 0.067, stand-
ard error (SE) = 0.026, P = 0.009) (See Supplementary Table S1). However, there were no significant association 
between hs-CRP and depression in women (β = 0.041, SE = 0.033, P = 0.223), and this showed the same pattern 
of association by sex as in the results of multiple logistic regression analysis.
Combined effect of hs-CRP and each covariate on depression. The results of subgroup analysis 
showing the combined effects of hs-CRP and sociodemographic variables on the prevalence of depression are pre-
sented in Tables 3 and 4. The association between BMI and hs-CRP in depression was only found in the “normal 
weight” group in men. The “normal weight” group with high hs-CRP levels were 2.46 times more likely to have 
depression than those with low hs-CRP levels.
The combined effect of smoking and hs-CRP on depression differed between men and women. The associa-
tion was linear in men and threshold-effect in women, with only current smoking showing a substantial associa-
tion with depression (OR: 5.77; 95% CI: 1.72–19.34). Residential area and hs-CRP were linearly associated with 
depression among men (OR: 2.68 and 2.51; 95% CI: 1.13–6.35 and 1.35–4.65, respectively), but the association 
was not profound in women. Compared to current married status, unmarried status showed considerable com-
bined effect with hs-CRP on depression only in men (OR: 3.12 and 3.13; 95% CI: 1.16–8.36 and 1.25–7.82, respec-
tively). Current alcohol use and hs-CRP were associated with depression in a threshold effect only in men (OR: 
2.68; 95% CI: 1.53–4.68). The association of hs-CRP with each age or educational attainment category did not 
show a considerable trend in combined effect to depression in both men and women. House income in both sex, 
and menopausal status in women was not associated with hs-CRP in depression. The results of subgroup analyses 
are presented in detail in Tables 3 and 4.
In addition, we performed subgroup analysis on men stratified by chronic medical diseases, which was considerably 
associated with depression in men (See Supplementary Table S2). In multivariate logistic regression analysis, the associ-
ation between hs-CRP and depression was significant in men without or with one chronic medical disease (adjusted OR 
2.12; 95% CI 1.06–4.24; P = 0.033). There was no association between hs-CRP and depression in men with two or more 
chronic medical diseases (adjusted OR 1.46; 95% CI 0.53–4.01; P = 0.462).
www.nature.com/scientificreports/
3Scientific RepoRts |          (2019) 9:1918  | https://doi.org/10.1038/s41598-018-36402-3
Discussion
Using hs-CRP categories recommended to assess the high risk for cardiovascular disease20, we found that depres-
sion was associated with high hs-CRP levels in men. After adjusting for potential confounding covariates, elevated 
hs-CRP (>3.0 mg/L) increased the prevalence of depression independently in men by nearly twofold. Moreover, 
the association between hs-CRP and depression in multiple linear regression analysis remained significant in 
men only.
Men Women
Depressive Nondepressive p-value Depressive Nondepressive p-value
Serum hs-CRP <0.0001 0.215
Low: less than or equal to 3.0 mg/L 78 (3.65) 2,059 (96.35) 211 (7.34) 2,664 (92.66)
High: above 3.0 mg/L 21 (8.90) 215 (91.10) 23 (9.79) 212 (90.21)
Age (years) 0.678 <0.0001
20–29 11 (4.37) 241 (95.63) 29 (8.66) 306 (91.34)
30–39 20 (4.67) 408 (95.33) 38 (6.61) 537 (93.39)
40–49 16 (3.43) 450 (96.57) 20 (3.39) 570 (96.61)
50–59 12 (2.86) 407 (97.14) 37 (6.17) 563 (93.83)
60–69 21 (5.02) 397 (94.98) 49 (9.53) 465 (90.47)
70–79 15 (4.78) 299 (95.22) 52 (13.58) 331 (86.42)
≥80 4 (5.26) 72 (94.74) 9 (7.96) 104 (92.04)
Educational attainment <0.0001 <0.0001
Elementary school and below 31 (8.68) 326 (91.32) 101 (43.16) 685 (23.82)
Middle school 10 (4.05) 237 (95.95) 33 (14.10) 289 (10.05)
High school 30 (3.87) 746 (96.13) 55 (23.50) 902 (31.36)
University or above 28 (2.82) 965 (97.18) 45 (19.24) 1,000 (34.77)
Equalized household income <0.0001 <0.0001
Quartile 1 (low) 43 (43.43) 363 (15.96) 98 (12.85) 517 (87.15)
Quartile 2 28 (28.28) 557 (24.49) 58 (10.25) 710 (89.75)
Quartile 3 16 (16.17) 658 (28.94) 56 (5.75) 793 (94.25)
Quartile 4 (high) 12 (12.12) 696 (30.61) 22 (4.31) 856 (95.69)
Marital status <0.0001 <0.0001
Married 47 (2.63) 1,743 (97.37) 118 (5.49) 2,033 (94.51)
Separated/divorced/widowed 23 (15.03) 130 (84.97) 82 (14.34) 490 (85.66)
Never married 29 (6.74) 401 (93.26) 34 (8.79) 353 (91.21)
Alcohol use status 0.822 0.347
No 27 (3.95) 656 (96.05) 145 (7.92) 1,685 (92.08)
Yes 72 (4.26) 1,618 (95.74) 89 (6.95) 1,191 (93.05)
Smoking status <0.0001 <0.0001
Non-smoker 47 (2.91) 1,568 (97.09) 203 (6.79) 2,788 (93.21)
Smoker 51 (6.86) 706 (93.14) 31 (26.05) 88 (73.95)
Chronic medical disease 0.002 <0.0001
None 48 (3.25) 1,431 (96.75) 107 (5.25) 1,930 (94.75)
One 21 (4.38) 459 (95.63) 57 (10.16) 504 (89.84)
Two or more 30 (7.25) 384 (92.75) 70 (13.67) 442 (86.33)
Residential area 0.313 0.249
Urban 34 (3.66) 896 (96.34) 87 (6.87) 1,180 (93.13)
Rural 65 (4.50) 1,378 (95.50) 147 (7.98) 1,696 (92.02)
BMI 0.026 0.019
Underweight 7 (11.67) 53 (88.33) 7 (4.90) 136 (95.10)
Normal weight 56 (4.16) 1291 (95.84) 133 (6.67) 1860 (93.33)
Overweight 30 (3.58) 809 (96.42) 77 (9.53) 731 (90.47)
Obesity 6 (4.72) 121 (95.28) 17 (10.24) 149 (89.76)
Menopause (females only) <0.0001
No 85 (5.51) 1459 (94.49)
Yes 149 (9.51) 1417(90.49)
Participants 99 (4.17) 2274 (95.83) 234 (7.52) 2876 (92.48)
Table 1. Sociodemographic characteristics of the study participants according to the presence and absence 
of depression (PHQ-9 ≥ 10). Categorical variables are presented as numbers and percentages. PHQ-9, patient 
health questionnaire-9; hs-CRP, high-sensitivity C-reactive protein; BMI, body mass index.
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Most literatures have revealed elevated inflammatory markers in patients with mood disorders such as depres-
sion21–23. A growing body of evidence suggests that diseases with immune activation and increased CRP levels 
predict increased risk of depression9,21,24. It is also suggested that, in addition to inflammatory conditions and 
neuro-inflammatory disorders, obesity25 and life stressors26 may also involve inflammation process and induce 
Depression (PHQ-9 ≥ 10)
Men Women
OR 95% CI p-value OR 95% CI p-value
Serum hs-CRP
  Low: less than or equal to 
3.0 mg/L 1.00 1.00
  High: above 3.0 mg/L 1.86 1.07 3.25 0.029 1.10 0.67 1.80 0.704
Age (years)
  20–29 1.00 1.00
  30–39 1.90 0.80 4.50 0.146 0.93 0.47 1.85 0.840
  40–49 1.34 0.52 3.44 0.547 0.33 0.15 0.74 0.007
  50–59 0.60 0.20 1.84 0.373 0.19 0.06 0.60 0.005
  60–69 0.75 0.24 2.41 0.633 0.15 0.04 0.50 0.002
  70–79 0.45 0.13 1.55 0.205 0.13 0.04 0.46 0.001
  ≥80 0.40 0.08 1.92 0.250 0.06 0.01 0.24 <0.0001
Educational attainment
  Elementary school and below 1.00 1.00
  Middle school 0.51 0.23 1.15 0.105 0.90 0.57 1.43 0.654
  High school 0.51 0.26 1.01 0.055 0.50 0.30 0.83 0.007
  University or above 0.48 0.23 1.02 0.055 0.46 0.26 0.83 0.009
Equalized household income
  Quartile 1 (low) 1.00 1.00
  Quartile 2 0.47 0.27 0.83 0.009 0.52 0.36 0.77 0.001
  Quartile 3 0.26 0.13 0.51 <0.0001 0.54 0.36 0.82 0.004
  Quartile 4 (high) 0.20 0.09 0.41 <0.0001 0.23 0.13 0.40 <0.0001
Marital status
  Married 1.00 1.00
  Separated/divorced/widowed 3.55 1.96 6.41 <0.0001 1.70 1.19 2.44 0.003
  Never married 2.52 1.33 4.79 0.005 1.51 0.81 2.84 0.196
Alcohol use status
  No 1.00 1.00
  Yes 1.21 0.74 1.98 0.460 0.94 0.69 1.28 0.673
Smoking status
  Non-smoker 1.00 1.00
  Smoker 2.16 1.38 3.38 0.001 4.04 2.51 6.49 <0.0001
Chronic medical disease
  None 1.00 1.00
  One 1.68 0.90 3.12 0.104 2.04 1.34 3.10 0.001
  Two or more 2.78 1.50 5.18 0.001 2.45 1.58 3.80 <0.0001
Residential area
  Urban 1.00 1.00
  Rural 1.07 0.68 1.68 0.773 1.12 0.84 1.50 0.437
BMI
  Underweight 1.93 0.75 4.97 0.170 0.72 0.32 1.62 0.429
  Normal weight 1.00 1.00
  Overweight 0.82 0.51 1.33 0.427 1.08 0.79 1.49 0.628
  Obesity 0.73 0.29 1.82 0.494 0.90 0.50 1.63 0.735
Menopause (females only)
  No 1.00
  Yes 2.12 0.84 5.34 0.110
Table 2. Results of the multivariate logistic regression analysis for the association between hs-CRP and 
depression (PHQ-9 ≥ 10). PHQ-9, patient health questionnaire-9; hs-CRP, high-sensitivity C-reactive protein; 
BMI, body mass index; OR, odds ratio; CI, confidence interval.
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clinical depression. Depression itself can also trigger subsequent CRP elevation27,28. Therefore, it can be said that 
depression and inflammation are intertwined, fueling and feeding off each other29. Although the underlying bidi-
rectional mechanisms are still poorly understood, our findings consistently show this association between depres-
sion and inflammation. The results of our study also support that of earlier epidemiological studies6,13,14,30,31.
Meanwhile, in accordance with previous studies16,32, we found an association between depression and elevated 
hs-CRP levels in men only. Several studies reported significantly elevated levels of pro-inflammatory cytokines, 
including interleukin-6 (IL-6), in men compared to women during sepsis33–35. Since CRP is produced by hepat-
ocytes largely under regulatory control of inflammatory cytokines, including IL-636, the biological difference of 
pro-inflammatory cytokines during inflammatory conditions by sex might be reflected in our results. Differential 
effects of sex hormones may also explain this sex difference. A review article of studies in sepsis showed that 
female sex hormones exhibit protective effects, whereas male sex hormones can be suppressive on cell-mediated 
immune responses37.
Men
Low hs-CRP 
(≤3.0 mg/L)
High hs-CRP
(>3.0 mg/L)
OR OR 95% CI p-value
Age (years)
  20–29 1.00 5.65 1.36 23.52 0.017
  30–39 1.00 0.50 0.07 3.82 0.503
  40–49 1.00 0.97 0.12 7.59 0.976
  50–59 1.00 9.18 2.83 29.79 <0.0001
  60–69 1.00 3.47 1.23 9.45 0.015
  70–79 1.00 1.77 0.48 6.57 0.393
  ≥80 1.00 1.38 0.13 14.30 0.786
Educational attainment
  Elementary school and below 1.00 2.35 0.99 5.60 0.053
  Middle school 1.00 3.33 0.81 13.66 0.094
  High school 1.00 3.30 1.36 7.99 0.008
  University or above 1.00 1.28 0.38 4.31 0.695
Equalized household income
  Quartile 1 (low) 1.00 1.96 0.95 4.02 0.069
  Quartile 2 1.00 1.95 0.71 5.32 0.195
  Quartile 3 1.00 1.78 0.39 8.04 0.456
  Quartile 4 (high) 1.00 2.58 0.55 12.12 0.229
Marital status
  Married 1.00 1.46 0.61 3.49 0.397
  Separated/divorced/widowed 1.00 3.12 1.16 8.36 0.024
  Never married 1.00 3.13 1.25 7.82 0.015
Alcohol use status
  No 1.00 2.18 0.69 6.86 0.184
  Yes 1.00 2.68 1.53 4.68 0.001
Smoking status
  Non-smoker 1.00 2.29 1.09 4.83 0.030
  Smoker 1.00 2.82 1.41 5.62 0.003
Chronic medical disease
  None 1.00 2.29 1.05 5.01 0.038
  One 1.00 2.45 0.86 6.95 0.093
Two or more 1.00 2.55 1.07 6.04 0.034
Residential area
  Urban 1.00 2.68 1.13 6.35 0.025
  Rural 1.00 2.51 1.35 4.65 0.004
BMI
  Underweight 1.00 3.84 0.59 25.19 0.161
  Normal weight 1.00 2.46 1.20 5.01 0.014
  Overweight 1.00 2.28 0.91 5.74 0.081
  Obesity 1.00 3.84 0.73 20.19 0.112
Table 3. Subgroup analysis of the association between hs-CRP and depression (PHQ-9 ≥ 10) stratified by 
sociodemographic variables in men. PHQ-9, patient health questionnaire-9; hs-CRP, high-sensitivity C-reactive 
protein; BMI, body mass index; OR, odds ratio; CI, confidence interval.
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A previous study14 reported an association between hs-CRP and depression in elderly women but not in 
young participants and suggested that this could be explained by hormonal changes during the aging process. 
Hormonal changes related to menstrual cycle was also suggested as a possible modulator between hs-CRP and 
depression13. By contrast, our subgroup analysis showed that the association of hs-CRP with menopausal status 
in women had no substantial effect on depression and depression was not related with hs-CRP in elderly women 
in our multivariate logistic analysis. For now, considering the possible uncontrolled confounding effects of oes-
trogen treatment and other hormonal changes in women, we cannot present any additional input regarding this 
debate. Body image perception38,39 and CRP-related genetic variation by sex could be also considered as other 
possible explanations of such discrepancy among studies40,41. Further research to examine the sex difference in 
Women
Low hs-CRP
(≤3.0 mg/L)
High hs-CRP
(>3.0 mg/L)
OR OR 95% CI p-value
Age (years)
  20–29 1.00 1.34 0.29 6.15 0.704
  30–39 1.00 1.39 0.47 4.10 0.554
  40–49 1.00 4.50 1.42 14.29 0.011
  50–59 1.00 1.26 0.37 4.28 0.717
  60–69 1.00 0.48 0.11 2.05 0.320
  70–79 1.00 1.04 0.42 2.59 0.938
  ≥80 1.00 2.19 0.41 11.79 0.361
Educational attainment
  Elementary school and below 1.00 0.98 0.49 1.97 0.957
  Middle school 1.00 2.86 0.98 8.33 0.055
  High school 1.00 1.36 0.52 3.52 0.532
  University or above 1.00 1.05 0.32 3.46 0.942
Equalized household income
  Quartile 1 (low) 1.00 1.06 0.53 2.11 0.864
  Quartile 2 1.00 1.08 0.42 2.81 0.874
  Quartile 3 1.00 2.12 0.92 4.93 0.080
  Quartile 4 (high) 1.00 <0.001 <0.001 >999.99 0.973
Marital status
  Married 1.00 1.44 0.78 2.68 0.247
  Separated/divorced/widowed 1.00 0.92 0.40 2.12 0.850
  Never married 1.00 2.34 0.75 7.34 0.143
Alcohol use status
  No 1.00 1.47 0.77 2.80 0.238
  Yes 1.00 1.24 0.65 2.36 0.515
Smoking status
  Non-smoker 1.00 1.00 0.58 1.72 0.985
  Smoker 1.00 5.77 1.72 19.34 0.005
Chronic medical disease
  None 1.00 1.48 0.75 2.90 0.259
  One 1.00 2.01 0.92 4.37 0.078
  Two or more 1.00 0.56 0.20 1.62 0.286
Residential area
  Urban 1.00 1.43 0.70 2.95 0.331
  Rural 1.00 1.34 0.75 2.39 0.329
BMI
  Underweight 1.00 <0.001 <0.001 >999.99 0.981
  Normal weight 1.00 1.12 0.53 2.34 0.775
  Overweight 1.00 1.10 0.51 2.37 0.818
  Obesity 1.00 2.28 0.81 6.43 0.120
Menopause (females only)
  No 1.00 1.64 0.77 3.50 0.203
  Yes 1.00 1.16 0.66 2.03 0.612
Table 4. Subgroup analysis of the association between hs-CRP and depression (PHQ-9 ≥ 10) stratified by 
sociodemographic variables in women. PHQ-9, patient health questionnaire-9; hs-CRP, high-sensitivity 
C-reactive protein; BMI, body mass index; OR, odds ratio; CI, confidence interval.
www.nature.com/scientificreports/
7Scientific RepoRts |          (2019) 9:1918  | https://doi.org/10.1038/s41598-018-36402-3
the association between hs-CRP and depression focusing on modulating effects of hormonal change, body image, 
genetic variation, and other possible related factors, is needed.
A study conducted in Germany reported that depression is considerably associated with CRP in obese men 
but not in non-obese men14. By contrast, a study comprising 6,901 Chinese participants showed that depression 
was profoundly negatively associated with BMI, with underweight being associated with worse depressive symp-
toms than other BMI groups42. In our results, hs-CRP was considerably associated with depression in men after 
adjusting BMI. These inconsistencies could be related to the differences in sample characteristics, such as the 
number of participants in the BMI categories, age groups, and ethnicity. The Korean general population analysed 
in this study primarily comprised individuals with relatively low BMI than those in other previous studies con-
ducted in Europe and North America. This difference among studies might confound the effect of BMI on the 
association between hs-CRP and depression.
In this study, a cut-off value of 3 for hs-CRP, which was originally defined in non-psychiatric studies, was used 
to categorize the participants. A previous study revealed that more than one-third of schizophrenia, unipolar 
depression, bipolar depression, and bipolar mania had CRP level >3 mg/L, and suggested that it might be related 
to increased risk of cardiovascular events in those patients43. Moreover, several other studies in the psychiatric 
field used the same cut-off to evaluate the association between hs-CRP and depression44, antidepressant con-
sumption9,45, reduced quality of life46, and mortality47 in psychiatric patients. Following the cut-off of hs-CRP in 
these studies, we presented our data with the same cut-off value.
The strengths of our study were that our data were obtained from a genetically homogeneous Korean adult 
population. This homogeneity is noteworthy because CRP levels are known to differ substantially between 
races48,49. All the participants of the study were Asians. Moreover, the BMI in our study population was relatively 
lower than that in several previous studies6,16,50, which could shed light on the association between hs-CRP and 
depression in the population with relatively low BMI. In addition, the scale used to define depression (PHQ-9) 
has been shown to be a valid scale for screening depression in the general population51.
There were also several limitations to our study. First, this study was conducted using cross-sectional associ-
ation data that are unable to clarify whether systemic inflammation precedes the onset of depression or occurs 
as a part of the somatic presentations of the depression. Second, there may be unrecognized confounding factors 
as in all observational studies. Such confounding factors could have contributed to the inconsistent association 
between hs-CRP and depression. For instance, acute infection52 and seasonal variation53,54 might impact CRP 
measures, and oestrogen therapy has been considered as a factor associated with hs-CRP levels among women55. 
However, relevant data were not collected in the 2016 KNHANES and thus were not included as variables in our 
analyses. Third, KNHANES was designed to collect data from non-institutionalized population only, and these 
data may represent only less severe depression because those who are severely depressed may be institutionalized 
or disproportionately chosen not to participate in the survey. This could limit the statistical power of the analysis 
by not reflecting the severity of depression. In addition, we did not include information on prior diagnosis for 
depression and treatment experience for the disorder, and this could confound the comparison among groups. 
Lastly, the lack of information on medications, particularly psychotropics, could attenuate the real association 
between hs-CRP and depression and might affect the results.
Despite these limitations, this study provides additional evidence that sex plays a critical role in the rela-
tionship between hs-CRP and depression. In addition, the relatively low BMI of the study population empha-
sizes the independent association of hs-CRP with depression after controlling for the effect of BMI, which 
is considered to be a major mediator of the inflammation-depression relationship. Our findings support the 
depression-inflammation relationship in the Asian population.
Conclusions
In conclusion, depression was considerably associated with hs-CRP only in men, even after adjusting for age, 
BMI, and other variables known to affect low-level inflammation. This finding suggests that a biological differ-
ence between men and women that can independently modify the relationship between hs-CRP and depression. 
Future investigations are needed to elucidate the possible association between systemic inflammation and depres-
sion by sex.
Methods
Study population and data. This study was conducted using data from the 2016 Korea National Health 
and Nutrition Examination Survey (KNHANES). The KNHANES is a nationwide population-based survey of the 
health and nutritional status of Koreans conducted by the Korea Centers for Disease Control and Prevention. The 
survey aims to evaluate the health and nutritional status of South Koreans and provide data for the development 
and evaluation of health policies and programs in Korea. The survey also produces statistical data regarding 
smoking, drinking, physical activities, and obesity for the World Health Organization and the Organization for 
Economic Cooperation and Development.
The KNHANES is annually conducted in twenty households throughout 192 regions, and 10,000 individuals 
aged ≥1 year are targeted for the survey. The survey pool is divided into three groups according to age: children 
(1–11 years), adolescents (12–18 years), and adults (≥19 years), and are categorized according to the different 
survey components. Adult participants completed the health interview survey that included the Patient Health 
Questionnaire-9 (PHQ-9), a depression screening scale. In this study, we included respondents aged ≥20 years 
who participated in the 2016 KNHANES, responded to the PHQ-9 questions, and had available results on hs-CRP 
levels. All subjects who participated in the survey signed an informed consent form. The 2016 KNHANES com-
plied with the tenets of the Declaration of Helsinki and the survey was exempted from IRB review, according to 
government regulation. Ethical approval was not required for this study as 2016 KNHANES provides secondary 
data that is publicly available, de-identified data.
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Measures. Patient Health Questionnaire-9 (PHQ-9). The Patient Health Questionnaire (PHQ)56 is a depres-
sion screening module that is a component of the Primary Care Evaluation of Mental Disorders instrument57. 
The PHQ-9 is a nine-item self-administered version of the PHQ and has been validated as a reliable depression 
screening tool and a measure of depression severity51. It is based on the Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition criteria for major depression58. The brevity and face validity of the PHQ-9 have 
made it a popular choice as a screening instrument of depression. Each item on the PHQ-9 is scored on a scale 
of 0 to 3, after which the scores are added to yield a total score ranging between 0 and 27. In its initial validation 
study, a score of 10 or higher had a sensitivity of 88% and a specificity of 88% for detecting major depressive dis-
orders51. The Korean version of the PHQ-9 also set the cut-off value at 10 to achieve a sensitivity of 81.8% and a 
specificity of 89.9% for identifying major depressive disorders59. In the current study, depression was defined as 
a PHQ-9 of ≥10.
Hs-CRP. Serum hs-CRP levels were measured via the Roche immunoturbidimetric ‘CRP’ and ‘C-reactive pro-
tein (latex) high sensitivity’ methods. Specimens (0.1–20 mg/L) were analysed using the high-sensitivity assay. 
Serum samples used for the analysis of hs-CRP were stored at 2–8 °C in refrigerated containers after blood test 
was taken. All laboratory analyses were performed within 24 hours of sample collection. To compare the prev-
alence of depression among different levels of hs-CRP, hs-CRP level of 3.0 mg/L was used. High hs-CRP levels 
were defined as hs-CRP levels >3.0 mg/L, which was the same as the cut-off stipulated by the American Heart 
Association and Centers for Disease Control and Prevention to indicate “high risk” for cardiovascular disorder20. 
Meanwhile, low hs-CRP levels were defined as <3.0 mg/L.
Covariates. Demographic (age and residential area), socioeconomic (educational attainment, household 
income, and marital status), and health-related (BMI, alcohol use status, smoking status, chronic medical dis-
eases, and menopausal status in women) covariates were included in this study. Chronic medical diseases that 
were reported to be directly or indirectly associated with hs-CRP levels, namely, hypertension60, diabetes melli-
tus61, dyslipidaemia62, coronary heart disease including myocardial infarction and angina pectoris63, stroke64, and 
rheumatoid arthritis65, were included as medical comorbidities.
Statistical analysis. Chi-square test was used to evaluate and compare the general characteristics of the study 
participants. Multivariate logistic regression analysis and multivariate linear regression analysis were used to 
examine the relationship between hs-CRP and depression. Subgroup analysis was performed to investigate the 
combined effect of hs-CRP and each covariate on depression. Odds ratios (ORs) and 95% confidence intervals 
(CIs) were calculated to compare the prevalence of depression according to hs-CRP levels. All analyses were per-
formed using SAS software, version 9.4 (SAS Institute, Cary, North Carolina, USA), and a P-value of <0.05 was 
considered significant.
Data Availability
This study analysed data from the 2016 KNHAES. All the KNHANES data are available to the public and can be 
downloaded from the KNHANES official website (http://knhanes.cdc.go.kr/).
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